Evidence map›Paper›PMID 37746793›Full record

ReviewClinical and translational allergy2023

Patient-physician interactions in hereditary angioedema-Key learnings from the coronavirus disease 2019 pandemic.

Marcus Maurer, Thomas Buttgereit, Markus Magerl, Kathrin Schön, Zsusanna Balla, Henriette Farkas

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and translational allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. The International/Canadian hereditary angioedema guideline.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 4 countries.

Marcus MaurerAngioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-4121-481X
Thomas ButtgereitAngioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-9389-1767
Markus MagerlAngioedema Center of Reference and Excellence (ACARE), Institute of Allergology, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-9218-5468
Kathrin SchönHAE Patient, Wiesbaden, Germany.
Zsusanna BallaHungarian Angioedema Center of Reference and Excellence (ACARE), Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0002-9041-5036
Henriette FarkasHungarian Angioedema Center of Reference and Excellence (ACARE), Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0003-2929-1721
Humboldt-Universität zu Berlin · DESemmelweis University · HUNational Patient Safety Foundation · US

Funding

CSL Behring
6 · The paper itself

Abstract

backgroundThe coronavirus disease pandemic and its containing measures have caused concerns for patients with hereditary angioedema (HAE) and their treating physicians. Both faced challenges surrounding interaction, and communication had to adapt to facilitate appropriate management. Specifically, the pandemic resulted in reduced in-person contact in clinics. Where possible, telemedicine appointments were offered and treatment outside the hospital setting was encouraged. BODY: The pandemic markedly affected patient-physician communication, which is essential to maintain partnerships and optimize care. Although patients with HAE are often experts in their condition, guidance by their physicians is essential, especially with the recent shift toward patient-centered management for rare diseases and shared decision-making (SDM). SDM enables patients to take control of their disease and allows the risks and benefits of treatment to be discussed with their physicians. This review explores perspectives from patients and physicians in the HAE clinical setting, particularly regarding their experiences with communication throughout the pandemic. We discuss the importance of SDM in rare diseases such as HAE, factors that impact effective communication, and potential solutions.

conclusionSince patient-centered care and SDM have particular relevance in rare diseases in general, we believe our findings could be transferrable and applicable in the management of other rare diseases.

Indexed as

COVID-19 pandemicdisease controlhereditary angioedemarelationshipshared decision-making

Identifiers

PMID37746793
PMCPMC10492262
OpenAlexW4386574804

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.